Patricia M. LoRusso

Nonlinear mixed effects dose response modeling in high throughput drug screens: application to melanoma cell line analysis

Jeffrey M. Trent, Darren Finlay, Kristiina Vuori, 2018, Oncotarget.

An Integrated Framework for Reporting Clinically Relevant Biomarkers from Paired Tumor/Normal Genomic and Transcriptomic Sequencing Data In Support of Clinical Trials in Personalized Medicine

Sara Nasser, Jeffrey M. Trent, Patricia M. LoRusso, 2014, Pacific Symposium on Biocomputing.

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Dan Lu, Amita Joshi, Patricia M. LoRusso, 2012, Cancer Chemotherapy and Pharmacology.

Analysis of variability in high throughput screening data: applications to melanoma cell lines and drug responses

Darren Finlay, Kristiina Vuori, Kuan-Fu Ding, 2017, Oncotarget.

Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.

Patricia M. LoRusso, Ronald A. Fleming, Barbara L. Weber, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors

Patricia M. LoRusso, Percy, A. Oza, 2008, Investigational New Drugs.

Phase 0 clinical trials: an answer to drug development stagnation?

Patricia M. LoRusso, P. LoRusso, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers

Patricia M. LoRusso, Weiwei Tan, K. Wilner, 2010, Clinical Cancer Research.